Abstract: The invention is directed to compounds of formula (1) and pharmaceutically acceptable salts thereof, methods for the preparation thereof, and methods of use thereof.

Abstract: There are provided compounds of the formula wherein X, Y, R1, R2, R3, R3, R4, and R5 are as described herein and enantiomers and pharmaceutically acceptable salts and esters thereof which are useful as anticancer agents.

Abstract: The present invention provides PLK1 inhibitor compounds of formula I: useful in the treatment or control of cell proliferative disorders, particularly oncological disorders. These compounds and formulations containing such compounds may be useful in the treatment or control of solid tumors, such as, for example, breast, colon, lung and prostate tumors and other oncological diseases such as non-Hodgkin's lymphomas. Also provided are intermediate compounds useful in the synthesis of compounds of formula I.

Abstract: There are provided compounds of the formula wherein R1, R2, R3, X, Y, Q, Ring A and Ring B are as described. The compounds exhibit activity as anticancer agents.

Abstract: A stator winding for a slotless motor is formed by winding a magnet wire 22 into a single layer coil 24. The coil 24 is deformed e.g., by pressing, to form a double layer web 26 which is rolled up end to end to form a cylindrical stator winding 20. The coil 24 is divided into a number of phase windings 27 extending between connection tappings 25. The magnet wire 22 is a multi-core magnet wire formed from a plurality of core wires 23. Each core wire 23 is an insulated single core wire. Optionally the core wires are twisted together. The core wires 23 are electrically connected together at the connection tappings 25 to form a plurality of parallel electrical paths or sub-windings.

Abstract: Disclosed are novel pyrazolo[3,4-d]pyrimidine derivatives that are inhibitors of Raf kinase. These compounds and their pharmaceutically-acceptable salts and esters are anti-proliferative agents useful in the treatment or control of proliferative disorders such as solid tumors, in particular breast tumor, colon tumor, lung tumor, prostate tumor, and melanoma. Also disclosed are a composition and a unit dose formulation comprising such a compound, or a pharmaceutically-acceptable salt or ester thereof, methods for making such compounds, and methods for using such compounds, or their pharmaceutically-acceptable salts or esters, in the treatment of proliferative disorders.

Abstract: There are provided compounds of the formula wherein X, Y and R1 to R8 are described herein along with the enantiomers, pharmaceutically acceptable salts and esters thereof. The compounds are useful as anticancer agents.

Abstract: There are provided compounds of the formula wherein X, Y, R1, R2, R3, R3, R4, and R5 are as described herein and enantiomers and pharmaceutically acceptable salts and esters thereof which are useful as anticancer agents.

Abstract: The invention is directed to compounds of formula (1) and pharmaceutically acceptable salts thereof, methods for the preparation thereof, and methods of use thereof.

Abstract: There are provided compounds of the formula wherein X, Y, R1, R2, R3, R3, R4, R5, R6 and R7 are as described herein and enantiomers and pharmaceutically acceptable salts and esters thereof. The compounds are useful as anticancer agents.

Abstract: An electric motor comprising a stator and a rotor, the stator comprising: a stator core having a yoke and a plurality of teeth extending inwardly from the yoke, a slot being formed between adjacent teeth; windings wound around the teeth; and a dielectric slot liner disposed between the stator core and the windings in each slot for insulating the stator core from the windings. Each slot liner comprises a body conforming the stator core in the slot and two ends each with a lip structure protruding relative to the body in a radial direction of the stator to increase the creepage distance between the winding and a distal end of a corresponding tooth of the stator core.

Abstract: The present invention provides PLK1 inhibitor compounds of formula I: useful in the treatment or control of cell proliferative disorders, particularly oncological disorders. These compounds and formulations containing such compounds may be useful in the treatment or control of solid tumors, such as, for example, breast, colon, lung and prostate tumors and other oncological diseases such as non-Hodgkin's lymphomas. Also provided are intermediate compounds useful in the synthesis of compounds of formula I.

Abstract: Novel intermediate compounds are disclosed. These compounds are useful in the synthesis of 4-aminopyrimidine-5-one derivatives that inhibit cyclin-dependent kinases, in particular cyclin-dependent kinase 4 (Cdk4). The 4-aminopyrimidine-5-one derivatives and their pharmaceutically acceptable salts have antiproliferative activity and are useful in the treatment or control of cancer, in particular solid tumors.

Abstract: A stator winding for a slotless motor is formed by winding a magnet wire 22 into a single layer coil 24. The coil 24 is deformed e.g., by pressing, to form a double layer web 26 which is rolled up end to end to form a cylindrical stator winding 20. The coil 24 is divided into a number of phase windings 27 extending between connection tappings 25. The magnet wire 22 is a multi-core magnet wire formed from a plurality of core wires 23. Each core wire 23 is an insulated single core wire. Optionally the core wires are twisted together. The core wires 23 are electrically connected together at the connection tappings 25 to form a plurality of parallel electrical paths or sub-windings.

Abstract: A gateway routes a packet from a user to a connected network utilizing a per-user routing table. A source address is extracted from the packet; a per-user routing table corresponding to the source address is found, the per-user routing table contains entries corresponding to one or more currently accessible networks for the user and the range of network addresses corresponding to the currently accessible networks; a destination address is extracted from the packet; an entry in the matching per-user routing table with a range of network addresses containing the destination address is sought; the packet is routed to a matching network if the destination address is contained within one of the ranges of network addresses for the currently accessible networks (“ranges”); and the packet is routed to a default network if the destination address is not contained within one of the ranges. Different users may access a different set of networks and select a desired network for access.

Abstract: There are provided compounds of the formula or the pharmaceutically acceptable salts thereof, wherein X, Y, Z, V1, V2, R1, R2, R3, R4 and R5 are herein described. These compounds are useful as anticancer agents.

Abstract: A method for conveying data communications network management information to an umbrella management system whereby network management information events are published on an information bus and received at a subscribing monitor interface located on the information bus. The monitor interface then converts the network management information events into umbrella management system-useable information and communicates the umbrella management useable information to the umbrella management system. In this manner, the umbrella management system is able to import valuable information pertaining to the devices and services that comprise the overall network. The monitor interface includes an adapter located on the information bus that subscribes to network management information events, a converter that formats the network management information events into data useable by the umbrella management system, and a forwarder that communicates the umbrella management system-useable data to the umbrella management system.

Abstract: Disclosed are novel pyrazolo[3,4-d]pyrimidine derivatives that are inhibitors of Raf kinase. These compounds and their pharmaceutically-acceptable salts and esters are anti-proliferative agents useful in the treatment or control of proliferative disorders such as solid tumors, in particular breast tumor, colon tumor, lung tumor, prostate tumor, and melanoma. Also disclosed are a composition and a unit dose formulation comprising such a compound, or a pharmaceutically-acceptable salt or ester thereof, methods for making such compounds, and methods for using such compounds, or their pharmaceutically-acceptable salts or esters, in the treatment of proliferative disorders.

Abstract: Multiple simultaneous network connections from a single PPP connection may be accomplished by utilizing a gateway in the following manner. A first network connection is established between the gateway and a first network. A first real network address for the user is then received, the first real network address assigned by the first network. Then, the gateway may establish a network session between the gateway and a second network and receive a second real network address for the user, the second real network address assigned by the second network. A virtual network address may be assigned to the user for network address translation purposes. Additional network connections may be added in a similar manner. Network address translation is then performed on packets traveling between the user and any of the network sessions. This allows each of the simultaneous network connections to gain the benefits of network address translation.

Abstract: A method for routing packets sent from a user to the internet is provided for systems in which the user is connected to a private network. The method includes: extracting a source network address from the packet; using said source network address to retrieve a user profile for the user; examining said user profile to determine whether to route the packet through the private network or to route the packet directly to the Internet; and routing said packet according to said profile. This allows a user or network provider to choose whether to route packets destined for the Internet directly to the Internet rather than through the private network, thus preventing excessive network traffic on the private network.